Shots:
- Roche & KlinRisk have received CE-mark approval for the AI-based Kidney Klinrisk Algorithm to assess progressive kidney function decline, integrated into the navify Algorithm Suite
- The chronic kidney disease algorithm panel combines the new Klinrisk Algorithm for early risk assessment with the CE-marked KFRE Algorithm for later disease stages, supporting care across the full CKD pathway; available in EU & UK, with later launch in the US, Middle East & Asia planned
- The Kidney Klinrisk Algorithm is an ML-based in vitro diagnostic tool designed to help clinicians predict progressive kidney function decline in adults with CKD stages G1–G4, as well as diabetic or hypertensive adults at risk for CKD
Ref: Roche | Image: Roche & KlinRisk | Press Release
Related News:- AVITA Medical Secures European CE Mark Approval for Recell Go to Advance Burn and Wound Healing
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
